Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
1998-11-20
|
pubmed:abstractText |
Here, we sought to obtain evidence that the progesterone receptor (PR) may be functional in ovarian cancer and regulated by estrogen. Megestrol acetate inhibited growth of the PR-positive PE04 ovarian carcinoma xenograft but not the PR-negative HOX 60 xenograft. PR concentration was higher in early-stage (I/II) tumors than in advanced-stage (III/IV) tumors (P = 0.007) and in tumors of endometrioid histology compared to other carcinoma subtypes (P = 0.009). Patients with a tumor PR concentration of >40 fmol/mg protein had significantly improved survival over those patients whose tumors contained <40 fmol/mg (P = 0.0007; log-rank). Evidence of PR regulation by estrogen was obtained by endocrine manipulation of the PE04 xenograft. PR content of PE04 xenografts fell from 145 to 7 fmol/mg protein in ovariectomized mice and was 2 fmol/mg in male mice. Administration of 17-beta-estradiol increased PR content to 745 fmol/mg. In primary ovarian carcinomas, PR was significantly associated with ER concentrations (P < 0.0001), suggesting regulation of PR levels by estrogen. This association was present for tumors of endometrioid histology (P < 0.0001) but not for those with serous histology (P = 0.31). These data point to the regulation of PR levels by estrogen in ovarian cancer and to a mediatory role for PR in the inhibition of growth induced by progestin.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Estrogens,
http://linkedlifedata.com/resource/pubmed/chemical/Megestrol Acetate,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1078-0432
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
4
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2245-51
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9748145-Animals,
pubmed-meshheading:9748145-Cell Division,
pubmed-meshheading:9748145-Estradiol,
pubmed-meshheading:9748145-Estrogens,
pubmed-meshheading:9748145-Female,
pubmed-meshheading:9748145-Humans,
pubmed-meshheading:9748145-Immunoenzyme Techniques,
pubmed-meshheading:9748145-Male,
pubmed-meshheading:9748145-Megestrol Acetate,
pubmed-meshheading:9748145-Mice,
pubmed-meshheading:9748145-Mice, Nude,
pubmed-meshheading:9748145-Neoplasm Transplantation,
pubmed-meshheading:9748145-Ovarian Neoplasms,
pubmed-meshheading:9748145-Receptors, Estrogen,
pubmed-meshheading:9748145-Receptors, Progesterone,
pubmed-meshheading:9748145-Transplantation, Heterologous,
pubmed-meshheading:9748145-Tumor Cells, Cultured
|
pubmed:year |
1998
|
pubmed:articleTitle |
Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen.
|
pubmed:affiliation |
Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital, Edinburgh, United Kingdom. s.langdon@icrf.icnet.uk
|
pubmed:publicationType |
Journal Article
|